share_log
Breakings ·  May 29 19:33
Baili Tianheng announced that the phase III clinical trial of BL-B01D1 (EGFR × HER3-ADC) for EGFR-sensitive locally advanced or metastatic non-small cell lung cancer where EGFR-TKI treatment failed was completed.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment